financetom
Business
financetom
/
Business
/
Fintech firm PROG Holdings beats Q2 revenue estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Fintech firm PROG Holdings beats Q2 revenue estimates
Jul 23, 2025 4:59 AM

Overview

* PROG Holdings ( PRG ) Q2 revenue of $604.7 mln beats analyst expectations, per LSEG data

* Adjusted EPS for Q2 beats consensus, reflecting strong execution in leasing business

* Progressive Leasing's GMV down 8.9% but within targeted write-off range

Outlook

* PROG Holdings ( PRG ) raises low end of 2025 revenue outlook to $2.45 bln

* Company expects 2025 net earnings between $120 mln and $125 mln

* PROG Holdings ( PRG ) sees Q3 revenue between $580 mln and $595 mln

* Company projects Q3 adjusted EBITDA between $57 mln and $62 mln

Result Drivers

* PROGRESSIVE LEASING - Strong execution in leasing business despite GMV headwinds and loss of key retail partner, per CEO Steve Michaels

* TECHNOLOGY INITIATIVES - AI-powered tools and digital optimization enhance customer engagement and efficiency, driving top-of-funnel engagement

* FOUR TECHNOLOGIES - Over 200% revenue growth and continued profitability, contributing positively to company's ecosystem

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $604.70 $585.70

Revenue mln mln (7

Analysts

)

Q2 Beat $1.02 $0.8 (7

Adjusted Analysts

EPS )

Q2 EPS $0.95

Q2 Net $38.50

Earnings mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the financial technology (fintech) peer group is "buy"

* Wall Street's median 12-month price target for PROG Holdings Inc ( PRG ) is $36.50, about 21.6% above its July 22 closing price of $28.61

* The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
ICICI Lombard remains cautious on private car insurance segment, says MD
ICICI Lombard remains cautious on private car insurance segment, says MD
Apr 25, 2023
Bhargav Dasgupta, the Managing Director and CEO of ICICI Lombard, one of India's leading general insurance companies believes that ease of doing business has helped the company launch new products and expand its reach in the market. However, he remains cautious on the motor segment, particularly the private car segment.
Ami Organics management explains semiconductor biz foray with Baba Chemicals acquisition
Ami Organics management explains semiconductor biz foray with Baba Chemicals acquisition
Apr 25, 2023
The acquisition of Baba Fine Chemicals by Ami Organics presents a significant growth opportunity for the company. With the semiconductor industry's high barriers to entry, the acquisition provides Ami Organics with a strong foothold in this market. The company can leverage Baba Chemicals' expertise in the semiconductor industry to target new markets and expand its business.
ABB global ups 2023 growth forecast and predicts strong double-digit revenue growth for second quarter
ABB global ups 2023 growth forecast and predicts strong double-digit revenue growth for second quarter
Apr 25, 2023
The leading global capital goods company ABB has revised its 2023 guidance upwards from 5 percent to nearly 10 percent. They have projected strong growth for the next quarter, expecting double-digit comparable revenue growth, following a calendar year.
Biocon-Serum deal: Won't raise stake for now but alliance not limited to Covid vaccines, says Adar Poonawalla
Biocon-Serum deal: Won't raise stake for now but alliance not limited to Covid vaccines, says Adar Poonawalla
Apr 25, 2023
Serum Institute of India CEO Adar Poonawalla says the company has a 15-year horizon on the vaccine deal with Biocon Biologics.
Copyright 2023-2026 - www.financetom.com All Rights Reserved